Boston Scientific said it plans to expand into "high-growth adjacent markets" and minimize its footprint in low-growth markets, among other measures, to achieve an up-to 8% organic revenue compound annual growth rate and a consistent double-digit adjusted earnings-per-share growth from 2018 to 2020. The company, which aims to reach a 25% adjusted operating margin this year, intends to release its Lotus Edge valve system in Europe in the fourth quarter and its Vercise DBS system in the US by early next year after FDA approval.
Strategy to maintain growth unveiled by Boston Scientific
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.